Pfizer

Pfizer Inc. said on May 10 the company will pay $11.6 billion to buy Biohaven Pharmaceutical Holding Co., making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs.

Longitudinal medical and prescription claims were used to assess opioid prescriptions and MME’s dispensed amongst migraine patients nine months prior to and nine months following Nurtec® ODT initiation.   Among the 14,019 with migraine who used opioids prior to initiating treatment with Nurtec ODT, approximately 41% had no opioid Rx fills in the 9 months […]

BioSpace looks at the 10 biggest drug approvals of 2021, headlined by Biogen’s Aduhelm (aducanumab) for Alzheimer’s disease and Pfizer and BioNTech’s COVID-19 vaccine Comirnaty.

The U.S. Food and Drug Administration approved Biohaven Pharmaceutical Holding Company Ltd.’s Nurtec ODT (rimegepant 75 mg) for the preventive treatment of migraine. Nurtec ODT is indicated for adult patients with episodic migraine, e.g. those who experience less than 15 headache days per month.

The U.S. Food and Drug Administration accepted AbbVie’s New Drug Application for atogepant, an investigational orally administered calcitonin gene-related peptide (CGRP) receptor antagonist for the preventive treatment of migraine in adults who meet criteria for episodic migraine.

A late-stage trial of Amgen Inc.’s Aimovig found that the experimental drug reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments.

Alder BioPharmaceuticals’ late-stage study data on its experimental treatment to prevent episodic migraine fell short of investors’ expectation.